Voya Financial Advisors’s Amedisys AMED Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-5,241
Closed -$480K 224
2023
Q2
$480K Sell
5,241
-76
-1% -$6.24K 0.06% 142
2023
Q1
$382K Sell
5,317
-838
-14% -$72.5K 0.05% 158
2022
Q4
$516K Sell
6,155
-2,037
-25% -$184K 0.07% 139
2022
Q3
$823K Buy
8,192
+60
+0.7% +$7.16K 0.11% 100
2022
Q2
$896K Buy
8,132
+153
+2% +$19.5K 0.11% 90
2022
Q1
$1.38M Sell
7,979
-134
-2% -$20K 0.16% 66
2021
Q4
$1.33M Buy
8,113
+2,838
+54% +$456K 0.15% 74
2021
Q3
$791K Buy
5,275
+532
+11% +$111K 0.1% 112
2021
Q2
$1.17M Sell
4,743
-9,225
-66% -$2.42M 0.15% 73
2021
Q1
$3.63M Buy
13,968
+2,590
+23% +$730K 0.14% 129
2020
Q4
$3.29M Buy
11,378
+3,122
+38% +$801K 0.14% 122
2020
Q3
$1.92M Buy
8,256
+1,786
+28% +$406K 0.1% 168
2020
Q2
$1.28M Buy
6,470
+583
+10% +$109K 0.07% 217
2020
Q1
$1.06M Buy
5,887
+663
+13% +$118K 0.06% 218
2019
Q4
$873K Buy
5,224
+334
+7% +$49.7K 0.04% 292
2019
Q3
$631K Buy
4,890
+447
+10% +$58.2K 0.03% 334
2019
Q2
$532K Buy
+4,443
New +$527K 0.03% 376

Other funds holding AMED

Voya Financial Advisors's AMED Position: Q3 2023 in Review

Voya Financial Advisors sold out of Amedisys (AMED) in Q3 2023, closing a stake of 5,241 shares — an estimated $480K sold.

Voya Financial Advisors first reported a position in AMED in Q2 2019 and held it in 17 quarters. The position peaked at $3.63M in Q1 2021. 286 funds tracked by Wall St. Rank hold AMED as of Q3 2023.

  • Voya Financial Advisors reported no remaining Amedisys position as of Q3 2023 after selling out during the quarter.
  • Voya Financial Advisors sold 5,241 Amedisys shares in Q3 2023, an estimated $480K.
  • Voya Financial Advisors first reported a position in Amedisys in Q2 2019 and held it in 17 quarters.
  • Voya Financial Advisors's Amedisys position peaked at $3.63M in Q1 2021.
  • 286 funds tracked by Wall St. Rank held Amedisys as of Q3 2023.

Based on Voya Financial Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.